1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>France

France To Replace AstraZeneca Booster With mRNA Jab In Under-55s

 
• By Ian Schofield

The French authorities believe that the “heterologous prime-boost” approach is justified in the case of people aged under 55 years who are due to receive their second dose of the AZ COVID-19 vaccine.

Covid south africa variant, covid-19 virus with african green flag
The South African coronavirus variant is one of those at large in France • Source: Alamy

The French government says that people under the age of 55 years who have had their first injection with the Oxford/AstraZeneca PLC COVID-19 vaccine should be given an mRNA vaccine as a booster in view of the incidence of unusual blood clots seen in younger populations who were given the AstraZeneca jab.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from France

French Bill Could Improve Clinical Research, But Further Action Is Required

 
• By Francesca Bruce

France’s simplification bill is a “first step” to improving the country’s clinical research environment, but more could be done to drive decentralized trials and simplify processes, says Leem, the French pharmaceutical industry association.

France’s New Carbon Footprint Measuring Method Could Guide Purchasing Decisions

 
• By Francesca Bruce

A new methodology for measuring pharmaceutical company carbon footprints could lead to a single standard for producing these calculations that is applicable to all medicines sold in France, said the industry association, Leem. However, it warned that there remains uncertainty about how the methodology will work in practice.

France Finally Passes Price Cutting Finance Bill – With Some Amendments

 
• By Francesca Bruce

Some changes to the contentious social security financing bill have been made, but industry and the government remain at odds over a €1.2bn drugs overspend.

France Gives Fresh Impetus To Economic Evaluations In Five Year Strategic Plan

 
• By Francesca Bruce

France’s health technology appraisal body, HAS, is putting more emphasis on the importance of economic evaluations in light of the rising costs of health technologies, including medicines and medical devices, and increasing budgetary pressures.

More from Europe

EU HTA Regulation: Don’t Forget About Vaccines, Industry Warns

 
• By Eliza Slawther

Europe’s vaccines industry wants to make sure immunizations “are not forgotten” by policymakers who are overseeing the EU Health Technology Assessment Regulation. It has highlighted several nuances of vaccines that should be addressed over the coming years.

EU Pharmacopoeia Adopts ‘Groundbreaking’ Cell Therapy Chapter, Seeks Feedback On Alternative Microbiological Tests

 
• By Neena Brizmohun

A new chapter that will be published in the European Pharmacopoeia soon is expected to provide a comprehensive framework for the production and quality control of cell-based preparations. Meanwhile, an existing chapter has been revised to facilitate the implementation of rapid microbiological testing methods.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include four new products, one of which is Tivdak, Pfizer/Genmab’s treatment for previously treated recurrent or metastatic cervical cancer.